All the events here are relevant to people working in dementia research. If you would like to add your own you can submit an event
Industry MasterClass in Drug Discovery and Development
July 10 @ 8:30 am - 6:30 pm
Taking therapeutics for neurodegeneration from concept to trial
Join leading experts from academia, biotech, pharma and drug development for a practical one day MasterClass exploring how discoveries in neurodegeneration can move from early target selection through to clinical trial strategy.
This in person event will examine the key stages of the drug discovery and development process, from identifying and validating targets, discovering and optimising leads, and navigating regulatory and commercial considerations, through to preparing for trial delivery.
The programme will bring together speakers from organisations including AstraZeneca, MSD, Lundbeck, AbbVie, Novartis, Roche, Eisai, Cervevance, Isomorphic, Denali, AstronautX, JNJ, Advent, Lilly and BMS.
Discussions will be hosted by Prof. Sarah Tabrizi and Prof. Mike Hanna from UCL.
Keynote
The Journey from an Academic Discovery to a Trial
Katerina Akassoglou
Gladstone Institute and Founder, Therini Bio
Co organisers
Fiona Ducotterd
Alzheimer’s Research UK UCL Drug Discovery Institute
Jim Ray
Belfer Neurodegeneration Consortium, MD Anderson
What will be covered
Attendees will discuss:
- How targets are selected to progress in biotech and pharma
- How leads are discovered and optimised into therapeutics
- How discoveries move from hit to candidate to formulation
- How regulatory and commercial considerations are navigated
- How to move towards a clinical trial
- How value is created for patients, providers and the pharmaceutical industry
- Where the field is heading next
Event details
Date: Friday 10 July 2026
Time: 8.30 am to 6.30 pm
Location: Mary Ward House, London
Format: In person
Capacity: Limited places available
Who should attend
This MasterClass is designed for researchers, clinicians, industry professionals, funders, translational scientists and anyone interested in how neurodegeneration therapeutics move from discovery science towards development and trial readiness.
Registration is now open.
A practical, high level course on translating neurodegeneration drug discovery into development strategy.
